Form D · Biotechnology
511 Therapeutics, Inc.
Cambridge, MA · CIK 0001946264
Offering snapshot reported Oct 30, 2026 · SEC filing
- Reported sold
- $500K Offering amount: $1M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 21, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 30, 2026 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Oct 6, 2022 | Initial | $49,999 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-603062
Source: Form D, filed Oct 30, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Yancen Lu | Director |
| Andrew Marshall | Director, Executive |
| Uwe B. Sleytr | Director |
| Shuguang Zhang | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1770 Massachusetts Avenue #511
Cambridge, MA, 02140
Cambridge, MA, 02140